drugset / Trial / NCT07668336

A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes

NCT07668336

Phase 3 Not yet recruiting 170 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

This study looks at how well a medicine called orforglipron works compared to another medicine called dulaglutide in pediatric participants aged 10 to less than 18 years with type 2 diabetes. The study will also check how safe these medicines are and how the body processes them. Participation in the study will last about 61 weeks.

Timeline

Start
2026-09
Primary completion
2030-03
Completion
2030-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dulaglutide Peptide Subcutaneous
Subject Orforglipron Small molecule Oral